Scarica l'app Stockscreener
25.43
0.57%
-0.152
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.58
Aprire:
$25.55
Volume 24 ore:
15.98M
Relative Volume:
0.26
Capitalizzazione di mercato:
$144.56B
Reddito:
$62.79B
Utile/perdita netta:
$9.84B
Rapporto P/E:
14.82
EPS:
1.7156
Flusso di cassa netto:
$10.38B
1 W Prestazione:
+0.57%
1M Prestazione:
-3.77%
6M Prestazione:
+3.35%
1 anno Prestazione:
-3.00%
Intervallo 1D:
$25.25
$25.60
Intervallo di 1 settimana:
$24.97
$25.77
Portata 52W:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.43 | 145.44B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,021.58 | 960.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.16 | 526.55B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
217.09 | 392.16B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
142.50 | 280.45B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.23 | 275.53B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Stock Under Pressure: Is This Pharma Giant a Deep Value Play or a Value Trap? - AD HOC NEWS
Pfizer: The Most Intriguing Value Play Of 2026 (NYSE:PFE) - Seeking Alpha
Pfizer’s Strategic Pivot: Obesity Drug Push and Regulatory Tailwinds - AD HOC NEWS
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer (NYSE:PFE) Trading 1.6% HigherWhat's Next? - MarketBeat
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus - TechStock²
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings - TechStock²
Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant - TipRanks
Pfizer’s Strategic Pivot Meets Skeptical Market Response - AD HOC NEWS
Bull Run: Why Pfizer Inc stock remains on watchlistsOil Prices & Risk Managed Investment Entry Signals - moha.gov.vn
Should Pfizer’s Oncology Win And Obesity Push Require Action From Pfizer (PFE) Investors? - simplywall.st
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy - Yahoo Finance
Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher - Yahoo Finance
Pfizer Ends Mid-Stage Lupus Skin Trial, Trimming a Small but Promising Autoimmune Option - TipRanks
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra” - TechStock²
Inside Pfizer's Oncology Performance Ahead of Q4 Results - The Globe and Mail
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff - BioSpace
Antidepressant Market Is Booming So Rapidly | Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline PLC, AstraZeneca - openPR.com
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy (NYSE:PFE) - Seeking Alpha
Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company - Yahoo Finance
Pfizer CEO Eyes Big Push Towards Obesity Drug Development In 2026 After $10B Metsera Acquisition - Stocktwits
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow (NYSE:PFE) 2026-01-13 - Seeking Alpha
(01/13/26) Top Picks 2026: Pfizer Inc. (PFE) - moneyshow.com
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra” - TechStock²
Stock Recap: Can Pfizer Inc lead its sector in growthQuarterly Market Review & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra - Reuters
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year - BioPharma Dive
UBS Likes Pfizer's MTSR Obesity Deal but Stays Neutral on PFE - Finviz
UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE - Yahoo Finance
Pfizer Talking to Trump Administration About Priority Vouchers - Bloomberg.com
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution - PharmExec.com
Pfizer CEO sees growth in international segments, modest growth for US in next few years - marketscreener.com
Pfizer CEO says expects to launch next-gen obesity assets acquired through Metsera buyout in 2028: JPM Conf - marketscreener.com
Update Recap: Is Pfizer Inc currently under institutional pressureJuly 2025 Opening Moves & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial - Benzinga
Pfizer’s Phase 3 C. Difficile Vaccine Study Targets a New Niche in the Adult Vaccine Market - TipRanks
Stock Watch: What’s Pfizer Hiding Behind COVID Product Decline And Patent Losses? - Citeline News & Insights
Lobbying Update: $60,000 of PFIZER INC lobbying was just disclosed - Quiver Quantitative
Nexus Investment Management ULC Boosts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Positive new data on Pfizer’s Braftovi regimen - The Pharma Letter
Pfizer (PFE) Valuation Check After Positive BREAKWATER Oncology Trial Update - simplywall.st
PFE Stock Price, Forecast & Analysis | PFIZER INC (NYSE:PFE) - Chartmill
13 Best Dividend Stocks Paying Over 6% - Insider Monkey
Madrigal’s $50M Pfizer Deal Sparks a New MASH Drug Power Play - MyChesCo
Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer - Lelezard
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certai - PharmiWeb.com
Pfizer Stock Just Flipped the Script: Crash, Cash, or Massive Comeback Play? - AD HOC NEWS
Pfizer announces positive results from Breakwater trial cohort 3 - marketscreener.com
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer - Business Wire
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.06%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):